
FDA Approves Zanvastro as First Targeted Therapy for Fatal Brain Disorder Alexander Disease
The U.S. Food and Drug Administration (FDA) approved Zanvastro (zilganersen), marking the first disease-modifying therapy available for pediatric and adult patients living with Alexander disease. Developed by Ionis Pharmaceuticals, the antisense oligonucleoti…








































